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Context: Depot medroxyprogesterone acetate (DMPA), a progestogen-only contraceptive injectable, has traditionally been formulated as a
crystalline suspension delivered intramuscularly (IM) at a dose of 150 mg/1.0 mL. A new, lower dose formulation of DMPA (104 mg/
0.65 mL) has been developed for subcutaneous administration (SC). Given its increasing global availability and public health relevance,
DMPA-SC was prioritized for inclusion as a new method referenced in the World Health Organization (WHO) Medical Eligibility Criteria
for Contraceptive Use (MEC), 5th Edition.
Objective: This systematic review evaluated the published peer-reviewed literature regarding the safety of DMPA-SC among women with
various characteristics or medical conditions. Results of this review informed the decision-making of a WHO Guideline Development Group
in order to include recommendations on contraceptive eligibility within the revised MEC.
Methods: We searched PubMed and Cochrane Library databases to identify all relevant evidence published in peer-reviewed journals
regarding the safety of DMPA-SC when used by women of reproductive age, particularly those with select characteristics or conditions
specified in the MEC, from inception through June 2015. The quality of each individual study was assessed using the system for grading
evidence developed by the United States Preventive Services Task Force.
Results: Fourteen studies met criteria for inclusion. Ten reported results relevant to DMPA users of varying age or with obesity,
endometriosis or HIV; four compared the safety of DMPA-SC and DMPA-IM when used by general populations of healthy women. A
randomized trial evaluating changes in bone mineral density among adult DMPA-SC and DMPA-IM users demonstrated no differences at
2 years of follow-up. Limited evidence reported no consistent differences in weight change or bleeding patterns according to age; however,
adolescents (b18 years) were not included in any studies. Similar contraceptive efficacy, weight change, bleeding patterns and occurrence of
other adverse effects among obese and nonobese DMPA-SC users were observed. Women with endometriosis using DMPA-SC over
6 months had minimal decreases in bone mineral density, weight gain, few serious adverse events and experienced improved pain symptoms.
Women living with HIV tolerated injection of DMPA-SC with rare complications. DMPA-SC and DMPA-IM also show therapeutic
equivalence and similar effects on weight gain, changes in bleeding patterns and reports of other adverse effects when these different delivery
systems were used by general populations of women.
Conclusion: Evidence for use of DMPA-SC by women with select conditions and characteristics including age, obesity, endometriosis or
HIV demonstrates that this method can generally be used safely in these contexts. Further, DMPA-SC and DMPA-IM appear to be
therapeutically equivalent with similar safety profiles when used by healthy women.
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Progestogen-only injectable contraception is highly
effective, reversible and safe for most women [1]. Depot
medroxyprogesterone acetate (DMPA), a progestogen-only
contraceptive injectable available since 1960, has tradition-
ally been formulated as a crystalline suspension delivered
intramuscularly at a dose of 150 mg/1.0 mL at one of twoD license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[2]. A newer, lower-dose formulation of depot medrox-
yprogesterone allows for subcutaneous delivery
(DMPA-SC). This alternative formulation reflects develop-
ment based on a 16% weight/volume solution resulting in a
final dose of 104 mg/0.65 mL that cannot be achieved
solely by diluting the original DMPA-IM formulation [3].
Sites for administration of DMPA-SC include the abdomen
and anterior thigh; however, subcutaneous administration in
the upper arm may also provide sufficient contraceptive
protection [4].
Absorption of medroxyprogesterone acetate (MPA) is
immediate following injection of DMPA-SC, resulting in
MPA levels greater than 0.2 ng/mL at 24 h, a conservative
threshold considered sufficient for contraceptive protection.
MPA levels peak at approximately 8 days post-injection and
remain greater than 0.2 ng/mL through 91 days [3]. For
women interested in continuing this method, re-dosing is
recommended every three months, similar to DMPA-IM.
Two large, noncomparative Phase 3 trials conducted across
more than 100 sites in North and South America, Europe and
Asia, including a total of nearly 2000 participants,
demonstrated that DMPA-SC is highly efficacious, safe
and acceptable to women [5].
The World Health Organization (WHO) convened
meetings of its Guideline Development Group (GDG)
during March 9–12, 2014, and September 24–25, 2014.
The purpose of these meetings was to review, and where
appropriate, revise specific evidence-based recommen-
dations included in the WHO Medical Eligibility
Criteria for Contraceptive Use (MEC) [6]. The GDG
consisted of 62 multi-disciplinary experts from 25
countries. In order to consider eligibility for inclusion
of DMPA-SC in the fifth edition of the MEC guidelines,
we conducted a systematic review of the safety of
DMPA-SC for use by women of reproductive age
according to the medical characteristics and conditions
specified in the document.2. Materials and methods
We searched the PubMed database to identify all relevant
evidence published in peer-reviewed journals in any
language from inception through June 2015 regarding the
safety of DMPA-SC in women of reproductive age. The
following search strategy was used: (“contraceptive agents,
female”[MeSH] AND (“injections”[MeSH] OR (“injec-
tions”[MeSH] OR “injections”[All Fields] OR “injectio-
n”[All Fields])) AND (subcutaneous[All Fields] OR
(“sc”[All Fields]) OR SQ[All Fields])) OR (“dmpa”
[All Fields] OR (depot[All Fields] AND (“medroxyproges-
terone”[MeSH] OR “medroxyprogesterone”[All Fields]))
OR (“medroxyprogesterone acetate”[MeSH] OR (“medrox-
yprogesterone”[All Fields] AND “acetate”[All Fields])
OR “medroxyprogesterone acetate”[All Fields] OR (“depo”[All Fields] AND “provera”[All Fields]) OR “depo
provera”[All Fields])) AND (subcutaneous[All Fields] OR
(“sc”[All Fields]) OR “SQ”[All Fields] OR “subQ”
[All Fields]”)). We also searched the Cochrane Library
database for any existing systematic reviews on the method
using the search terms “depot medroxyprogesterone SC or
SQ or subcutaneous.” Additionally, we hand-searched
reference lists of identified articles for further citations of
interest. We did not attempt to identify unpublished articles
or abstracts from scientific conferences or contact any
individual authors.
We were interested in including direct evidence to answer
the following question: Among reproductive age women
with medical conditions or specific characteristics within
the MEC, does the use of DMPA-SC increase the risk of
adverse events or worsen the condition compared with
nonuse of the method? We also searched for indirect
evidence addressing whether healthy reproductive age
users of DMPA-SC experienced any increased risk of
adverse events compared to nonusers. Studies reporting
comparisons from women using either no contraception or
nonhormonal contraception were preferred; however,
because examining whether the safety profile of
DMPA-SC is similar to DMPA-IM, we also included
studies where users of DMPA-IM formed the comparison
group. Additionally, because assessing the safety among
women with various conditions or characteristics who use
the same form of contraception may be informative in
addressing our review question, we also included studies
simply reporting adverse outcomes among users of
DMPA-SC, particularly to determine differences in safety
according to age or obesity status.
2.1. Study selection
We reviewed titles and abstracts and the full article, when
necessary, to identify studies for inclusion. Reference lists
from identified articles and key review articles were
hand-searched to locate any additional articles. Individual
case reports and articles investigating other formulations of
DMPA were excluded as were publications that reported on
a subset of data published elsewhere in an already included
larger analysis.
2.2. Study quality assessment
Evidence was summarized and systematically assessed
using standard abstract forms [7] and the quality of each
study was assessed using the system for evaluating
evidence (Appendix A) developed by the United States
Preventive Services Task Force (USPSTF) [8]. Table 1
summarizes the direct evidence from studies investigating
DMPA-SC use in women with various medical conditions
or characteristics and Table 2 summarizes indirect
evidence from studies comparing DMPA-SC with use
of DMPA-IM among healthy women. Studies were
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author (M.G.).
2.3. Data synthesis
We did not compute summary measures of associations
due to heterogeneity of study designs, study populations, and
outcome measures collected.3. Results
Of the 296 articles identified by the search strategy,
14 satisfied the review inclusion criteria. Twelve articles
presented results for seven studies investigating
DMPA-SC use among women with four conditions or
characteristics identified in the WHO MEC, including
obesity [5,9–15], age [9–11] endometriosis [16–18] and
HIV [19]. Four of these articles report on results from
three multinational pivotal Phase 3 contraceptive trials,
including results from two noncomparative trials of
DMPA-SC users conducted at sites in North and South
America, Europe, and Asia, and a randomized, evaluator-
blinded trial comparing DMPA-SC and DMPA-IM users
conducted in the United States, Canada, and Brazil
[5,9–11]. Additional studies included four randomized-
controlled trials [16–19] and four reports from a
prospective cohort study [12–15]. As the occurrence of
adverse events among women with medical conditions or
characteristics using DMPA-SC is relevant for this
review, two Phase 3 randomized-controlled noninferior-
ity trials evaluating DMPA-SC use compared with
leuprolide and one Phase 2 randomized controlled trial
evaluating DMPA-SC compared with elagolix in the
setting of endometriosis, were considered as noncom-
parative prospective studies for the purposes of this
review [16,17].
Three articles provide indirect evidence derived from one
of the Phase 3 trials comparing the safety of DMPA-SC and
DMPA-IM formulations when used by general populations
of healthy women [9,11,20]. In addition, an observational
study conducted in Uganda and Senegal reporting safety
outcomes among healthy past users of DMPA-IM who
switched to DMPA-SC was included [21].
3.1. Obesity
3.1.1. Contraceptive efficacy
Two fair quality reports presented results on three Phase 3
contraceptive trials and described contraceptive efficacy
among obese women using DMPA-SC [5,9]. These studies
included sexually active adult women with a history of
regular menstruation and excluded women with recent
hormonal contraceptive use, known pregnancy or infertility
or other medical contraindications for use. In the study by
Kaunitz et al., approximately one in four of the entire study
population (N = 534) of had a BMI N30 kg/m 2:
DMPA-SC(n=65 of 266) and IM (n=69 of 268) [9]. Nopregnancies were reported among any DMPA-SC or
DMPA-IM users during the first year of follow-up. In
Years 2 and 3, no women randomized to DMPA-SC
experienced pregnancy during 3565 and 5241 woman-cycles
of exposure, while the treatment-failure cumulative preg-
nancy rates among DMPA-IM users were reported as 0.75%
(3442 woman-cycles of exposure) and 0.8% (5241 woman-
cycles of exposure) respectively. In a pooled analysis of two
noncomparative trials of nearly 2000 women by Jain et al.
obese participants (BMI N30 kg/m2) accounted for 17.5% of
the study sample in the Americas and 6.3% of the study
sample in European and Asian sites combined. No
pregnancies were reported during 1 year of follow-up,
reflecting a total of 6227 injections and 16,023 women-
cycles of exposure [5]. In both studies, women underwent
routine pregnancy testing at baseline and prior to each
subsequent injection; additionally, the authors excluded
cycles during which no intercourse or use of concurrent
barrier contraception were reported to calculate contracep-
tive efficacy.
3.1.2. Weight change
A fair quality report byWesthoff et al. presented results of
a pooled analysis from three Phase 3 contraceptive trials
regarding changes in weight among DMPA-SC users by
BMI class and across DMPA-SC and DMPA-IM users [11].
While there were no significant differences reported in
weight gain across BMI groups (≤25,N25 to≤30,N30 kg/m2),
all DMPA (SC and IM) users gained weight. The median
change in body weight among users of DMPA-SC
compared to DMPA-IM from enrolment though months
12, 24 and 36 were presented in a line graph; weight gain
increased over time and was similar across users of the two
methods. At month 36, the median weight change in the
DMPA-SC group (n=65) was 4.5±8.5 kg and 5.8±8.7 kg
in the DMPA-IM group (n=56).
Another small prospective cohort study evaluated weight
change among five normal BMI (18.5–24.9 kg/m2),
five obese (30.0–39.9 kg/m2), and five extremely obese
(≥40 kg/m2) DMPA-SC users during 26 weeks of follow-
up, or two injection cycles [13]. All women were noted to
gain weight during the trial (mean range 0.62–2.59 kg).
While normal BMI users gained more weight than obese or
extremely obese women from baseline to 13 weeks and from
13 weeks to 26 weeks post-injection, the findings did not
achieve statistical significance. Moreover, no difference in
weight change by BMI class over the duration of the study
period (baseline to week 26) was observed (p= .29).
3.1.3. Other adverse effects
Arias et al. described changes in bleeding patterns among
obese and nonobese users of DMPA-SC and DMPA-IM
included in three Phase 3 contraceptive trials [10]. All
participants were asked to record daily bleeding patterns in a
diary; data were analyzed according to 30-day intervals
starting from the time of the first contraceptive injection
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bleeding in the first 30 days following the first injection
(no figure reported), which was not unexpected as all women
received their DMPA-SC injection within five days of the
onset of their regular menstrual cycle. The majority (51%) of
women reported 1–7 days of bleeding or spotting during this
period in the noncomparative Americas trial. Bleeding and
spotting gradually decreased over time; at 12 months, all
studies noted that a majority of women experienced
amenorrhea. When changes in bleeding patterns were
assessed by BMI group (≤ 25, N25 to ≤30, N30 kg/m2),
no consistent differences were apparent.
Four poor-quality reports from a small prospective cohort
study evaluated a number of potential adverse effects of
DMPA-SC use among five normal BMI (18.5–24.9 kg/m2),
five obese (30.0–39.9 kg/m2), and five extremely obese
(≥40 kg/m2) DMPA-SC users during 26 weeks of follow-up,
or two injection cycles [12–15]. One reported serummeasures
of progesterone (P4), estradiol (E2) and medroxyprogesterone
acetate (MPA) collected weekly, bi-weekly and monthly, as a
means to quantify follicular development and ovulation among
obese and nonobese DMPA-SC users [12]. Following the first
week of injection, no users were observed to have a P4 level
≥3 ng/mL. Median E2 levels did not exceed 100 ng/mL for
any BMI class. Though median medroxyprogesterone acetate
(MPA) levels remained within a therapeutic contraceptive
range for all BMI categories throughout the study period, these
levels were noted to be lower in obese compared with normal
BMI women. Another report of changes in serum androgen
markers (total testosterone (T), total androstenedione (A),
dehydroepiandrosterone sulfate (DHEAS), 3α-androstenediol
glucuronide and sex hormone-binding globulin (SHBG))
measured at week 13 and week 26 during exposure to
DMPA-SC described net decreases in all groups for total T,
total A and SHBGwith no change in the serum levels of other
markers; no significant differences in the observed serum
levels of any androgenmarkerswere noted amongBMI groups
[13]. When a number of cardiometabolic risk markers
measured at baseline and at 18 weeks were compared across
BMI groups, no differences were noted except for the
Disposition Index, a measure of β-cell compensation for
insulin resistance, which decreased in obese women (−286)
and increased in nonobese women (188.5) (p=.04) [14].
Finally, small decreases in mean bone mineral density (BMD)
at the lumbar spine measured by Dual Energy X-ray
Absorbtiometry (DEXA) were noted at 18 weeks post-
enrolment among all DMPA-SC-users (normal: −0.083,
obese: −0.091. extremely obese: −0.112, p=.89), though no
difference was reported across BMI groups [15]. All
participants had normal BMD at baseline.3.2. Age
3.2.1. Changes in bone mineral density
Kaunitz et al. reported changes in bone mineral density
during use of DMPA-SC in a Phase 3 clinical trial [9]. Adultwomen, aged 18–35 years, with normal measures of BMD
at baseline were randomized to use of DMPA-SC (n=266)
or DMPA-IM (n=268). All women experienced a decrease
in BMD during use of DMPA through up to three years of
study follow-up. At the end of year one, DMPA-SC users
had less of a decrease in BMD compared to IM users at the
lumbar spine (−2.4% vs. –3.4%, p= .021); however, no
significant changes were noted at the hip. In years two and
three, the median percent changes in BMD among
DMPA-SC compared to DMPA-IM users were not statis-
tically different. Six women discontinued DMPA at two
years during the trial and underwent a repeat BMD
assessment 1 year following discontinuation; it was not
specified whether they used SC or IM formulations. Four of
these women showed an increase in BMD at the hip and all
five women with BMD measurements at the lumbar spine
showed an increase. Two women in each group showed
complete recovery of BMD back to baseline. Four fractures
were noted among 3 DMPA-SC and 1 DMPA-IM users
(foot, rib, ankle and wrist) and none were assessed to be due
to osteoporosis.
3.2.2. Weight changes
Westhoff et al. reported on weight changes experienced
by adult women of various age groups during exposure to
DMPA-SC or DMPA-IM based on data from Phase 3 trials
[11]. Though all women experienced weight gain during
use of either method over time that was similar, there were
no consistent differences in the distribution of weight
change across age groups (b25, 25–35, N35 years). The
authors note that there was a trend toward higher weight
gains among women N35 years in the North/South
American noncomparative Phase 3 trial (p= .076). How-
ever, in the DMPA-SC/IM Phase 3 trial including among
women aged 18–35 years, weight gain was significantly
higher among womenb25 years using DMPA-SC com-
pared to women ages 25 to 35 years at month 9 (p= .025)
and 12 (p= .003).
3.2.3. Changes in bleeding patterns
Arias et al. reported no consistent differences in bleeding
patterns across age groups (≤25, 25–35, N35 years) among
DMPA-SC users in Phase 3 trials [10]. In the noncompar-
ative Americas trial (n=722), women between the ages of
25–35 had higher rates of amenorrhea, while women aged
b25 and N35 years reported more instances of bleeding and
spotting (pN .05) at months 6, 9 and 12. In the SC/IM study,
73% of DMPA-SC users between 25 and 35 years reported
amenorrhea at 12 months compared to 52.8% of women
under age 25 using the method (p= .008); no differences
were noted in bleeding patterns across groups at months 3, 6
or 9 in this sample.
3.3. Endometriosis
Two randomized controlled noninferiority trials were
designed to assess DMPA-SC and leuprolide as treatment
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Phase 2 randomized, controlled trial investigated use of a
GnRH antagonist, elagolix, compared with DMPA-SC
[18]. All studies recruited reproductive-age women with a
surgical diagnosis of endometriosis and persistent pain
symptoms attributable to their condition prior to use of
DMPA-SC. One hundred fifty-three women from sites in
Europe, Asia, Latin America, or New Zealand and 136
DMPA-SC users from Canada and the United States
contributed data to the reports lead by Crosignani and
Schlaff. Carr et al. conducted their Phase 2 trial at 78
centers across the United States and randomized 84 women
to DMPA-SC.
In these three fair quality studies, there were no
significant changes to vital signs or standard laboratory
assays. In addition, two trials noted minimal weight gain
among DMPA-SC users; median changes in body weight
were +0.70 and +0.95 kg at month six of treatment, and
+0.9 kg and +1.30 kg at the end of the study period
(18 months). These studies also reported that the median
percent change in BMD at the hip (−0.3, −0.5) and lumbar
spine (−1.1, −1.0) at Month 6 were minimal and BMD
recovery at twelve months following discontinuation of
DMPA-SC was observed. Carr et al. noted that mean percent
decreases in bone mineral density after six months of use
were minimal (spine: −0.99%; femur: −1.29%). Generally,
all studies also reported a decrease in bleeding days over
time. Many DMPA-SC users reported a variety of drug-
related adverse events; however, serious adverse events were
rare in all studies.
3.4. HIV
A randomized, cross-over study by Polis et al. was
conducted to assess acceptability of SC versus IM
administration of DMPA among clinically well women
living with HIV who expressed interest in injectable
contraception and attended community-based health
clinics in Rakai, Uganda. Women were randomized to
either receive DMPA-SC (n=179) or DMPA-IM (n=178)
at enrollment and then received the alternative formulation
3 months later. Participants completed a pre-injection
baseline questionnaire and post-injection questionnaires at
baseline, 3 months and 6 months where they recorded
adverse effects. In general, there were no differences in
the report of any side effects overall in the first three
months among DMPA-SC and DMPA-IM users; however,
women in the SC group tended to report more fatigue
(4.4% vs. 0%, pb .01). Few women reported “a lot” of
skin irritation with their injection (0–5%), though more
skin irritation was noted among DMPA-SC users at 3 and
6 months after enrollment. Women also reported more
skin irritation associated with a recent injection of
DMPA-SC compared to DMPA-IM received 3 months
earlier (pb .01). Among women who received DMPA-SC
at baseline and DMPA-IM at 3 months, more menstrualirregularity was noted at 6 months compared to those who
received DMPA-IM at baseline and DMPA-SC at
3 months (10.9% vs. 4.4%, p= .03). Two deaths, one in
each randomization group, were reported as unlikely to be
due to DMPA exposure. Additionally, four pregnancies,
two in each randomization group, were reported; all
occurred between baseline and the 3-month follow-up
visit. All women underwent baseline urine hCG pregnancy
testing prior to DMPA administration.
3.5. Healthy women
Four articles compared various safety outcomes among
healthy women using DMPA-SC and DMPA-IM
[9,11,20,21]. Three report on evidence derived from a
Phase 3 randomized, evaluator-blinded contraceptive trial
comparing women, ages 18 to 35 years, who used
DMPA-SC (n=266) or DMPA-IM (n=268) through up to
3 years of follow-up, described earlier in this review [9]
Among healthy women, DMPA-SC and DMPA-IM appear
to be equivalently efficacious [9], associated with similar
changes in bone mineral density during use that are unrelated
to acute osteoporotic fracture [9], and mean weight gains
(DMPA-SC: 4.5±8.5 kg, DMPA-IM: 5.8±8.7 kg 4.5
(mean ± SD) were not statistically different across methods
through 36 months of follow-up [11].
In the primary report of the Phase 3 comparative trial
results, treatment-emergent adverse events, or those that
developed for the first time or were present and worsened
in either intensity or frequency following treatment with
DMPA SC or IM were recorded. At least one adverse
event was reported among 81.4% of DMPA-SC users and
77.8% of DMPA-IM users; 54.4% and 56.0% of reported
AEs were determined to be associated with the study
drug. The most common drug-related event was weight
gain (DMPA-SC: 12.2%, DMPA-IM: 14.3%) in both
groups. Serious adverse events (SAE) were rare
(DMPA-SC: 3.8%, DMPA-IM: 2.3%); and, with the
exception of one unintended pregnancy in the DMPA-IM
group, none of the reported SAEs were associated with
study treatment. Among both DMPA-SC and DMPA-IM
users, unpredictable bleeding and spotting decreased over
time and amenorrhea increased. At the end of Year 1,
62.6% of DMPA-SC users and 61.1% of DMPA-IM users
denied any bleeding or spotting; at the end of Year 2,
71.0% of DMPA-SC users and 80.0% of DMPA-IM users
reported amenorrhea. The pattern of amenorrhea by
30-day month intervals among users of both methods
demonstrated similar frequencies over time. It was also
noted that there were more injection site reactions present
in the SC compared to the IM group; however, the
frequencies were not further specified; Jain et al. reported
that 1.6% of SC users in the European/Asia trial and 9.7%
of the SC users in the Americas trial experienced injection
site reactions defined as the presence of pain, granuloma
or atrophy [5].
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single site data from the trial to review changes in
coagulation and inflammation markers among 14 women;
four participants received DMPA-SC and ten participants
received DMPA-IM. The investigators measured D-dimer,
C-reactive protein (CRP), antithrombin (AT), factor
VIIIc, activated partial thromboplastin time (aPTT) and
aPTT plus activated protein C (APC) at baseline and 6
and 12 months. Decreases in D-dimer and aPTT were noted
among all users, and no other alterations were noted among
other measured markers. There were no differences across
DMPA formulations.
Finally, a prospective, open-label observational study
conducted in Uganda (n=120) and Senegal (n=242)
invited healthy, reproductive age women currently using
DMPA-IM to switch to DMPA-SC and then assessed
several safety outcomes during 3 months following
administration [21]. When asked to compare which
injection caused more skin irritation, just over two thirds
of women in Uganda (69.2%) and nearly half of the
women in Senegal (43.0%) noted no difference; among
those who noted a distinction, most women in both
samples reported skin irritation more frequently with IM
injection (19.2% and 44.6%, respectively). No serious
adverse events related to DMPA-SC and no pregnancies
were reported. Of the 34 adverse events (28 in Uganda; 6
in Senegal) noted among 25 participants, 10 were deemed
attributable to DMPA-SC use. These were mild to
moderate in severity; three were associated with skin
irritation and the rest attributed to common side effects of
DMPA, and all resolved without sequelae.4. Discussion
Eight reports from three studies, including two Phase 3
trials and a small prospective cohort, of fair to poor
quality suggest that the safety of DMPA-SC use among
obese women is similar to nonobese women; and, obese
users of DMPA-SC and DMPA-IM experience similar
adverse effects [5,9–15]. Further, limited evidence from
these Phase 3 trials also suggest that the safety of
DMPA-SC use among subgroups of premenopausal adult
women is also similar and that these women experience
infrequent and comparable adverse effects when
DMPA-SC and DMPA-IM are used in these populations;
no studies reported on adverse outcomes among adoles-
cents [9,11]. For the condition of endometriosis, three
Level II-3 reports of fair quality presented prospective
non-comparative descriptive data for women with the
condition who used DMPA-SC [16–18]. There was no
evidence that DMPA-SC contributed to a worsening of
their condition or an increased frequency of any other
serious adverse events. Of note, DMPA-SC also proved
therapeutically beneficial in reducing signs and symptoms
of endometriosis during use and for months followingdiscontinuation in all studies, though this was not a
primary outcome for this review. One Level-I randomized,
cross-over study evaluated various adverse effects of
DMPA-SC and DMPA-IM use among clinically well adult
women living with HIV in Uganda [19]. Serious adverse
events were rare and no different across treatment arms,
and it was unlikely that any reported deaths were
associated with exposure to DMPA. Generally, the
findings from this study appear reassuring, but the
authors did not comment on participants' clinical status
over time, which may have bearing on their susceptibility
to and report of various adverse effects. Further, the study
did not investigate critical health outcomes informing
assessments for eligibility of women living with HIV and
progestogen-only contraception, namely risks of HIV
transmission or disease progression due to exposure to
this new DMPA formulation, accounting for its assess-
ment as poor quality.
Taken together, the existing evidence among healthy
women suggests that DMPA-SC and DMPA-IM appear to
be therapeutically equivalent. Additionally, the two
formulations demonstrate similar effects on serum estra-
diol levels and high contraceptive efficacy [9]. Similar
effects on weight gain, changes in bleeding patterns, and
reports of other adverse effects have also been demon-
strated. It appears that users of DMPA-SC may experience
injection site reactions more frequently, but these are rare,
typically mild to moderate in severity and generally
resolve without further intervention [5,9,19].
The bulk of safety information identified for this review is
derived from Phase 2 and 3 contraceptive trials, including
two noncomparative prospective studies and one randomized
trial comparing DMPA-SC and DMPA-IM, and three
randomized, controlled trials providing prospective, non-
comparative descriptive data among women with endome-
triosis using DMPA-SC [5,9,11,16–18,20]. While these
studies do include women from study sites around the world,
supporting generalizability of the results, both comparative
and noncomparative studies had high dropout rates over time
(N20%), possibly introducing bias. These studies and the
reports generated from them received support (funding,
statistical expertise, etc.) from the pharmaceutical company
manufacturing DMPA-SC; this involvement could possibly
introduce systematic bias into the review, as drug companies
tend toward publishing only favorable results [22]. Addi-
tionally, a number of small studies with limited exposure to
treatment with DMPA and short follow-up periods provided
information on surrogate endpoints for disease that may not
capture the true effect of DMPA-SC exposure on clinically
relevant outcomes [12–15,20,23]. Given the limited scope of
data we identified to inform assessments of safety among
DMPA-SC users with the various characteristics or condi-
tions of age, obesity status, endometriosis and HIV,
determination of medical eligibility criteria for contraceptive
safety required evaluating data obtained from studies of
other contraceptives with similar mechanisms of action,
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that the evidence we identified comparing DMPA-SC and
DMPA-IM demonstrated therapeutic equivalence of the
formulations, suggesting that such comparisons may be
well founded.Table 1
Levels of evidence
Levels of evidence
Level I Evidence obtained from at least one properly designed
randomized controlled trial.
Level II-1 Evidence obtained from well-designed controlled trials without
randomization.
Level II-2 Evidence obtained fromwell-designed cohort or case–control analytic
studies, preferably from more than one centre or research group.
Level II-3 Evidence obtained from multiple time series with or without the
intervention. Dramatic results in uncontrolled experiments
could also be regards as this type of evidence.
Level III Opinions of respected authorities, based on clinical experience,
descriptive studies, or reports of expert communities.5. Conclusion
Following a review of the evidence in accord with
WHO guideline development processes, the GDG
determined that eligibility recommendations for proges-
togen-only injectables should not change with inclusion
of DMPA-SC as a new method in this category,
referenced in the WHO MEC, 5th Edition. No unique
critical safety concerns for this formulation emerged for
women with select characteristics or conditions using
DMPA-SC or in comparison to DMPA-IM. WHO will
continue to monitor the body of evidence informing
these recommendations and will re-evaluate the recom-
mendations, as needed, should new evidence necessitate
reconsideration. Subsequent to the consultation, two new
articles were published and included in this review
[18,21]; the results from these studies offer additional
supporting evidence and remain consistent with the
updated recommendations.
In conclusion, women eligible to use DMPA have an
option to choose the formulation and delivery route that
matches their preferences without compromising safety.Notably, DMPA-SC may offer important service delivery
advantages over DMPA-IM. For example, several studies
demonstrate that self-administration of DMPA-SC is feasible
and associated with similar continuation and satisfaction
rates as DMPA-IM [24–26].Acknowledgments
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Table 1
DMPA-SC evidence in women with medical conditions.
Author, Date, 
Funding, 
Location
Study Design, 
Study Period and 
Follow-up
Study population Condition Comparison 
Groups
Results/Outcomes Strengths/Weaknesses Quality
Kaunitz et al., 
2009[9]
Pfizer
United States, 
Canada, Brazil
Randomized, 
evaluator-blinded 
Phase III trial
2-3 years
April 2001 –
Sept 2004
Women, ages 18 to 35, 
with history of regular 
menstruation and 
desiring injectable 
contraception 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
within 10 months of 
enrolment, known 
pregnancy or infertility 
or medical 
contraindications
DMPA-SC 
N=266
DMPA-IM
N=268
Obesity Normal vs. 
Overweight 
vs. Obese
DMPA-SC vs. 
DMPA-IM 
users
DMPA-SC
N=266
DMPA-IM
N=268
Weight (kg)
Mean + SD 69.3+17.7 71.2+19.0
Range 40.0-142.9 42.2-140.6
BMI (kg/m2)
Mean + SD 26.1+6.1 26.4+6.4
Range 15.6-54.0 17.8-50.1
n (%) n (%)
< 25 142 (53.6) 142 (53.0)
>25 to < 30 58 (21.9) 57 (21.3)
>30 65 (24.5) 69 (25.7)
Outcome: Contraceptive efficacy
Treatment-failure cumulative pregnancy rate
DMPA-SC DMPA-IM
Year 1 0% 0%
Year 2 0% 0.75%
Year 3 0% 0.8%
(95% CI, 0.00-2.37)
Pearl Index
DMPA-SC DMPA-IM
Year 1 0 0
Year 2 0 0.35
Year 3 0 0.24
(95% CI, 0.00-0.70)
Strengths
Multi-country design
Accounted for times of no 
intercourse and use of 
barrier contraception in 
calculation of efficacy
Weaknesses
Not powered to detect 
difference in contraceptive 
efficacy between methods 
or across BMI classes
Failure reported for all 
weight/BMI classes 
combined
High dropout rate; 43.6% 
(116/266)  DMPA-SC users 
and 40.7% (109/268) 
DMPA-IM users completed 
2 years’ treatment
II-2, 
fair
Jain et al., 
2004[5]
Support not 
stated
North and 
South America, 
Europe, Asia
Pooled analysis of 
2 Phase III trials 
1 year
Not stated
Women, ages 18 to 49, 
with history of regular 
menstruation and 
desiring injectable 
contraception 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
Obesity Normal vs. 
Overweight 
vs. Obese
All DMPA-
SC users
Outcome: Contraceptive efficacy
Americas
n =722
European/Asia
n=1065
Weight (kg)
Mean + SD 66.5+ 16.7 62.6+ 11.3
Range 38.8-164.9 35.0-113.2
BMI (kg/m2)
< 25 403 (55.8) 779 (73.1)
>25-30 189 (26.2) 219 (20.6)
>30 126 (17.5) 67 (6.3)
Strengths
Multi-country design
Accounted for times of no 
intercourse and use of 
barrier contraception in 
calculation of contraceptive 
efficacy
Weaknesses
II-2, 
fair
within 10 months of 
enrolment, known 
pregnancy or infertility 
or medical 
contraindications
N= 722    (Americas)
N= 1065  (Eur/Asia)
No pregnancies reported in the trial with total of 6227 injections 
during 16, 023 woman-cycles of exposure.
68.7% of 722 women from 
Americas and 80.4% of 
1065 women from 
Europe/Asia completed the 
study
Westhoff et al, 
2007[11]
Pfizer
North and 
South America, 
Europe, Asia
Pooled analyses 
from two non-
comparative 
Phase III trials 
[5]and RCT 
comparing IM and 
SC DMPA[9]
1 year, 2-3 years
Women, ages 18 to 49, 
with history of regular 
menstruation and 
desiring injectable 
contraception 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
within 10 months of 
enrolment, known 
pregnancy or infertility 
or medical 
contraindications
Obesity Normal vs. 
Overweight 
vs. Obese
DMPA-SC vs. 
DMPA-IM 
users
Outcome: Weight change
Median weight gain at 36 months (overall)
DMPA-SC:4.5 + 8.5 kg
DMPA-IM: 5.8 + 8.7 kg
No significant differences in median weight gain by BMI 
subgroups (< 25, >25 to < 30, >30 kg/m2) in any study. Data 
presented graphically in article.  
Strengths
Multi-country design
Height and weight measured 
at baseline and weight 
measured every 3 months 
during follow-up
Weaknesses
No non-POC comparison 
group
High dropout over time
II-2, 
fair
Segall-
Gutierrez et al., 
2010[12] , 
2012[14], 
2012[13], 
2013[15]
Anonymous 
donor
United States
Prospective 
cohort
Up to 26 weeks 
(2 injections of 
DMPA SC 104)
7 month period; 
year(s) not stated
Women, ages 18 to 35 
years
Excluded women with 
prior use of DMPA or 
other POC in 3-6 month 
prior to enrolment, or 
other medical 
contraindications
Normal BMI 
(18.5-24.9 kg/m2) 
n=5
Obese BMI
(30.0-39.9 kg/m2)
n=5
Extremely obese BMI 
(> 40 kg/m2)
n=5
Obesity Normal vs. 
Obese vs. 
Extremely 
obese
All DMPA-
SC users
Outcome: Weight change[13]
Time interval since injection
BMI 0-13 wk 13-26 wk
Normal +1.95 kg +0.64 kg
Obese +0.41 kg +0.58 kg
Extremely
Obese
+0.52 kg +0.1 kg
(p=0.06) (p=0.06)
No difference seen in weight changes across BMI classes from 
baseline to week 26; p = 0.29 
Outcome: Other adverse events
1. Changes in serum androgen markers[13]
Measured total testosterone (T), total androstenedione (A), 
Strengths
Includes women of very 
high BMI
Weaknesses
Small sample size
No non-POC comparison 
group
Short follow-up
Measures biomarkers and 
not direct outcome
II-2, 
poor
DHEAS, 3   -androstanediol glucuronide (reflects 5    -reductase 
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activity) and SHBG at baseline, week 13 and week 26
Net decreases in all groups for Total T, Total A and SHBG from 
baseline to week 26; no change in other markers. No significant 
differences in serum levels of any androgen markers between 
groups.
2.  Changes in cardio-metabolic risk markers[14]
No significant differences in changes in risk markers between 
obese and normal weight groups, with the exception of Disposition 
Index (measure of B-cell compensation for insulin resistance) 
which decreased I obese women (-286) and increased in non-obese 
women (188.5) (p-0.4)
3. Changes in bone mineral density (BMD)[15]
At baseline, no differences in mean BMD of lumbar spine 
measured by DXA across groups. 
Noted small decreases in BMD across all groups with no 
significant differences between groups on repeat scan at 18 weeks 
after first injection (midway through injection #2)
4. Follicular development and ovulation[12]
No subject had P4 levels > 3ng/mL after week one following 
injection.
Median E2 levels never > 100 ng/mL among all BMI categories.
Median MPA levels remained consistently above levels needed to 
suppress ovulation for all BMI categories at 12 weeks post-
injection 1 and 14 weeks for injection 2; however, MPA levels in 
obese lower than normal BMI women.
Arias et al., 
2006 [10]
Pfizer
North and 
South America, 
Europe, Asia
Pooled analyses 
from two non-
comparative 
Phase III trials[5]
and  RCT 
comparing IM and 
SC DMPA[9]
1 year, 2-3 years
Women, ages 18 to 49, 
with history of regular 
menstruation and 
desiring injectable 
contraception 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
Obesity, Age Normal vs. 
Overweight 
vs. Obese
Adult women
All DMPA-
SC users
Outcome: Changes in bleeding patterns
Nearly all women experienced some degree of bleeding across 
trials.
Americas: 51% of women reported bleeding or spotting for 1 to 7 
days in first 30 days after injection. Incidence of irregular bleeding 
or spotting decreased over time. Similar trends noted in 
Europe/Asia trial.
Bleeding at 12 months
Strengths
Multi-country design
Weaknesses
High dropout over time
II-2, 
fair
within 10 months of 
enrolment, known 
pregnancy or infertility 
or medical 
contraindications
N= 722    (Americas)
N= 1065  
(Eur/Asia)
N=266
(RCT- DMPA SC)
Americas: 62% amenorrhea, 19% spotting
Europe/Asia: 52% amenorrhea,. 27% spotting 
Reports no consistent differences in bleeding patterns among either 
age or BMI subgroups. 
Westhoff et al, 
2007[11]
Pfizer
North and 
South America, 
Europe, Asia
Pooled analyses 
from two non-
comparative 
Phase III trials[5]
and  RCT 
comparing IM and 
SC DMPA [9]
1 year, 2-3 years
Women, ages 18 to 49, 
with history of regular 
menstruation and 
desiring injectable 
contraception 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
within 10 months of 
enrolment, known 
pregnancy or infertility 
or medical 
contraindications
Age Adult women
DMPA-SC 
and DMPA-
IM users
Outcome: Weight change
Reports no consistent differences in the distribution of weight 
change across age group (<25, >25 to 35, >35 years). 
Strengths
Multi-country design
Height and weight measured 
at baseline and weight 
measured every 3 months 
during follow-up
Weaknesses
No non-POC comparison 
group
II-2, 
fair
Kaunitz et al., 
2009[9]
Pfizer
United States, 
Canada, Brazil
Randomized, 
evaluator-blinded 
Phase III study
2-3 years
April 2001 –
Sept 2004
Women, ages 18 to 35 
years, desiring 
injectable contraception 
with history of regular 
menstruation 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
within 10 months of 
enrolment, known 
pregnancy or infertility 
or medical 
contraindications
Age Adult women 
DMPA-SC vs. 
DMPA-IM 
users
Outcome: Changes in bone mineral density (BMD)
Characteristic DMPA-SC
N=266
DMPA-IM
N=268
Age
Mean + SD 25.9+4.9 25.8+4.8
Range 18.0-35.9 18.0-35.7
Decrease in total hip BMD of > 5% from 
baseline
DMPA-SC DMPA-IM
Year 1 13/166 7.8% 20/162 12.3%
Year 2 30/106 28.3% 34/101 33.7%
Year 3 35/63 55.6% 28/54 51.9%
Decrease in total lumbar spine BMD of > 5% 
from baseline
Strengths
Multi-country design
Powered to detect a 2% 
difference in the percent 
change of BMD over two 
years with 60% dropout rate
Weaknesses
High dropout rate over time
I, good
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DMPA-SC 
N=266
DMPA-IM
N=268
DMPA-SC DMPA-IM
Year 1 34/166 20.5% 40/162 24.7%
Year 2 40/106 37.7% 52/102 51.0%
Year 3 36/62 58.1% 21/53 39.6%
During both first and second years, observed median BMD 
decreases from baseline at hip and lumbar spine were smaller in SC 
group compared to IM group; finding significant at year 1, though 
not in years 2 and 3.
BMD recovery at 12 months after discontinuation (N= 6) 
Hip: 4/6 showed increase with 2 having full recovery
Lumbar spine: 5/5 showed increase in BMD, 2 with full recovery, 
however, no specification of IM vs. SC use
Four fracture AEs were reported among 3 DMPA-SC users and 1 
DMPA-IM user at the foot, rib, ankle and wrist; no fracture was 
clinically assessed to be due to osteoporosis
Crosignani et 
al., 2006[16]
Funding not 
stated
Europe, Asia, 
Latin America, 
New Zealand
Randomized, 
evaluator-blinded, 
comparator-
controlled non-
inferiority trial 
As we are only 
interested in 
adverse events 
among women 
with 
endometriosis 
using DMPA-SC, 
and not in 
comparative 
therapeutic 
effects, we 
considered this a 
non-comparative 
prospective study.
18 months; 6 
months treatment 
with 12 months 
follow-up
Women, ages 18 to 49 
years, with 
laparascopically 
diagnosed 
endometriosis and 
persistent pain 
symptoms
DMPA SC 104
N= 153
Endometriosis DMPA-SC No clinically relevant changes in hematology, chemistry assays, 
nonfasting lipids, or urinalyses. 
No clinically significant changes in systolic or diastolic blood 
pressure 
Median weight change at 6 months: +0.70 kg
Median weight change at 18 months:   +0.90 kg
Median % change in BMD among DMPA-SC users
Hip
Month 6 -0.5
Month 18 -0.2
Lumbar spine
Month 6 -1.0
Month 18 -0.4
Changes in bleeding patterns: Noted increase in amenorrhea over 
time: 19.5% at month 3, 24.5% at month 6
Adverse events reported as (> 5%) drug-related side effects
DMPA-SC
n=152
n(%)
Nausea 17 (11.2)
Strengths
Multi-country design
Included women with 
surgically confirmed 
diagnosis
Used validated measures to 
collect pain data
Randomized sample of 
DMPA users
Weaknesses
No comparison group
II-3, 
fair
Headache 5 (3.3)
Breast pain 8 (5.3)
Intermenstrual bleeding 19 (12.5)
Hot flushes 9 (5.9)
Any drug-related adverse event during treatment: 50.7%
Any serious adverse event: 3.9%
Schlaff et al., 
2006[17]
Pfizer
Canada and 
United States
Randomized, 
evaluator-blinded, 
comparator-
controlled non-
inferiority trial 
As we are only 
interested in 
adverse events 
among women 
with 
endometriosis 
using DMPA-SC, 
and not in 
comparative 
therapeutic 
effects, we 
considered this a 
non-comparative 
prospective study
18 months; 6 
months treatment 
with 12 months 
follow-up
Women, ages 18 to 49 
years, with 
laparascopically 
diagnosed 
endometriosis and 
persistent pain 
symptoms
DMPA-SC, n=136
Endometriosis DMPA-SC No clinically relevant changes in hematology, chemistry assays, 
nonfasting lipids, or urinalyses. 
No clinically significant changes in systolic or diastolic blood 
pressure
Median weight change at 6 months:     +0.95 kg
Median weight change at 18 months:   +1.30 kg
Median % change in BMD among DMPA-SC users
Hip
Month 6 -0.3
Month 18 0
Lumbar spine
Month 6 -1.1
Month 18 0.2
Changes in bleeding patterns: Median number of 35.0 bleeding or 
spotting days in first 90 days, 24.1 days in second 90 day reference 
period. 
Adverse events reported as (> 5%) drug-related side effects
DMPA-SC
n=130
n(%)
Injection site reaction 9 (6.9)
Headache 10 (7.7)
Insomnia 3 (2.3)
Libido decrease 3 (2.3)
Instermenstrual bleeding 7 (5.4)
Hot flushes 3 (2.3)
Any drug-related adverse event during treatment: 47.7%
Any serious adverse event: 2.2%
Strengths
Multi-country design
Included women with 
surgically confirmed 
diagnosis
Randomized sample of 
DMPA users
Weaknesses
High dropout rate during 6 
month treatment period, 
35.3% DMPA-SC 
Among women who 
completed 6 month 
treatment period, only 58% 
of DMPA-SC  users 
completed 12 month follow-
up
II-3, 
fair
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Carr et al., 
2014[18]
Neurocrine 
Biosciences, 
BC, Syneract 
and Evofem
United States
Randomized, 
double-blind, 
controlled trial
As we are only 
interested in 
adverse events 
among women 
with 
endometriosis 
using DMPA-SC, 
and not in 
comparative 
therapeutic 
effects, we 
considered this a 
non-comparative 
prospective study
December 2006 to 
November 2008
24 week treatment 
period with 24 
week post-
treatment 
observation 
Women, ages 18 to 49 
with laparascopically 
diagnosed 
endometriosis and 
persistent pain 
symptoms
DMPA-SC, n=84
Endometriosis DMPA-SC No clinically relevant changes in laboratory safety parameters,vital 
sign measurements or ECG readings noted.
Mean % change in BMD amond DMPA-SC users at week 24
Spine -0.99%
(-1.61 to -0.37)
Femur -1.29%
(-1.80 to -0.77)
Mean percentage of days with any bleeding during treatment: 
30.4% + 2.4%
Most common adverse events among DMPA-SC users
Headache 17.9%
Nausea 15.5%
Nasopharyngitis 10.7%
Upper respiratory infection 11.9%
Mood swings 11.9%
No deaths occurred in the study period; 6 SAEs among DMPA-SC 
users deemed unrelated to use.
No pregnancies occurred among users of DMPA-SC.
Strengths
Multi-country design
Included women with 
surgically confirmed 
diagnosis
Randomized sample of 
DMPA users
Weaknesses
High dropout rate during 
treatment period, 60% 
(51/84) 
II-3, 
fair
Polis et al., 
2013[19]
Society of 
Family 
Planning, Bill 
and Melinda 
Gates Institute 
for Population 
and 
Reproductive 
Health, Dr. 
Ronald Gray, 
Pfizer
Uganda
RCT cross-over 
study
6 months
April 2012 –
March 2013
Clinically well women 
living with HIV, ages 
18 to 45, interested in 
injectable contraception 
recruited from 
community-based 
health clinics
DMPA SC 104
N=179
DMPA IM 150
N=178
HIV DMPA-SC vs. 
DMPA-IM
Serious adverse events
2 deaths: one in each randomization group
1: febrile illness of unknown etiology, possibly immune 
reconstitution inflammatory syndrome after ART initiation
1: severe anemia, possibly due to zidovudine or malaria
4 pregnancies reported; 2 in each randomization group, all 
occurring between baseline and 3 mo visit, no comment on 
concurrent ART use
Skin irritation
Most women reported little or no skin irritation with IM and SC 
injection (95 -100%); however, more skin irritation was noted 
among DMPA-SC users (p < 0.01 at 3 and 6 months). 
Other adverse effects
No significant differences in report of any side effect overall in last 
3 months among women who received SC and IM at enrolment. 
No differences in menstrual irregularity, more days bleeding than 
before DMPA initiation, heavier bleeding, no bleeding, dizziness, 
headaches, decreased wetness during sex, or decreased libido.  
Women in the SC group reported more fatigue than IM group 
(4.4% vs. 0%, p < 0.01)
At 6 months, women who received baseline SC/ 3-m IM reported 
more menstrual irregularity compared to women who received 
baseline IM/ 3-m SC (10.9% vs. 4.4%, p =0-03); no other 
differences noted.
Strengths
First study to evaluate 
DMPA-SC among women 
living with HIV
Weaknesses
No non-HIV comparison 
group
Not powered to detect 
differences in serious 
adverse events
Unclear whether 
pregnancies due to method 
failure, possible ART 
interactions, or result of 
undetected early pregnancy 
at time of initial injection
Did not report on 
participants clinical status 
over time and relation to 
report of adverse effects
I, poor
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Table 2
Criteria for grading the internal validity of individual studies.
Study design Criteria
Systematic reviews ▪ Comprehensiveness of sources/search strategy used
▪ Standard appraisal of included studies
▪ Validity of conclusions
▪ Recency and relevance
Case–control studies ▪ Accurate ascertainment of cases
▪ Nonbiased selection of cases/controls with exclusion criteria applied equally to both
▪ Response rate
▪ Diagnostic testing procedures applied equally to each group
▪ Appropriate attention to potential confounding variables
RCTs and cohort studies ▪ Initial assembly of comparable groups:
▪ For RCTs: adequate randomization, including concealment and whether potential confounders were distributed
equally among groups
▪ For cohort studies: consideration of potential confounders with either restriction or measurement for adjustment
in the analysis; consideration of inception cohorts
▪ Maintenance of comparable groups (includes attrition, crossovers, adherence, contamination)
▪ Important differential loss to follow-up or overall high loss to follow-up
▪ Measurements: equal, reliable, and valid (includes masking of outcome assessment)
▪ Clear definition of interventions
▪ All important outcomes considered
▪ Analysis: adjustment for potential confounders for cohort studies, or intention-to-treat analysis for RCTs
Diagnostic accuracy studies ▪ Screening test relevant, available for primary care, adequately described
▪ Study uses a credible reference standard, performed regardless of test results
▪ Reference standard interpreted independently of screening test
▪ Handles indeterminate results in a reasonable manner
▪ Spectrum of patients included in study
▪ Sample size
▪ Administration of reliable screening test
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Table 2
DMPA-SC evidence in healthy women.
Author, Date, 
Funding, Location 
Study Design and 
Follow-up
Study population Condition Comparison 
Groups
Results/Outcomes Strengths/Weaknesses Quality
Kaunitz et al., 
2009[9]
Pfizer
United States, 
Canada, Brazil
Randomized, 
evaluator-blinded 
Phase III trial
2-3 years
April 2001 –
Sept 2004
Women, ages 18 to 35, 
with history of regular 
menstruation and 
desiring injectable 
contraception 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
within 10 months of 
enrolment, known 
pregnancy or infertility 
or medical 
contraindications
DMPA-SC 
N=266
DMPA-IM
N=268
Healthy 
women
DMPA-SC vs. 
DMPA-IM
Frequency of AEs associated with study drug
DMPA-SC: 54.4% (143/263)
DMPA-IM: 56.0% (149/266)
More injection site reactions present in SC vs. IM group 
(mild to mod severity); not further specified.
Note: Jain et al. [5] noted injection site reactions (pain, 
granuloma or atrophy) among SC users
European/Asia trial: 1.6%
Americas trial: 9.7%
Frequency of serious adverse events
DMPA-SC: 3.8% (10/263)
DMPA-IM: 2.3% (6/266)
No serious adverse event determined to be associated 
with study treatment by investigators, excluding an 
unintended pregnancy in the DMPA-IM group.
Changes in bleeding patterns
Year 1
DMPA-SC: 62.6% amenorrhea
DMPA-IM: 61.1% amenorrhea
Year 2
DMPA-SC: 71.0% amenorrhea  
DMPA-IM: 80.0% amenorrhea
Trends in amenorrhea by 30-day month presented in 
line graph in article; very similar for SC and IM.
Treatment-failure cumulative pregnancy rates
Strengths
Multi-country design
Weaknesses
High dropout rate over time
I, good
DMPA-SC DMPA-IM
Year 1 0% 0%
Year 2 0% 0.75%
Year 3 0% 0.8%
(95% CI, 0.00-2.37)
Pearl Index
DMPA-SC DMPA-IM
Year 1 0 0
Year 2 0 0.35
Year 3 0 0.24
(95% CI, 0.00-0.70)
Goldstein et al., 
2007[20]
University of 
Vermont 
College of 
Medicine
United States
Secondary 
analysis of single 
site data from  
RCT[9]
1 year
Women, ages 21 to 35 
years
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
within 10 months of 
enrollment, known 
pregnancy or infertility 
or medical 
contraindications 
(including prior VTE)
DMPA SC (n=4)
DMPA IM (n=10)
Healthy 
women
DMPA-SC vs. 
DMPA-IM
Outcome: Changes in coagulation and inflammation 
markers
Measured D-dimer, C-reactive protein (CRP), 
antithrombin (AT), factor VIIIc, activated partial 
thromboplastin time (aPTT) and aPTT plus activated 
protein C (APC) at baseline, 6 mo and 12 mo.
Noted significant decreases in D-dimer and aPTT; no 
other markers different. No differences between the two 
routes of administration. 
Strengths
Weaknesses
Small sample size
No non-POC comparison group
Measures biomarkers and not direct 
outcome of VTE
II-2, 
poor
Westhoff et al, 
2007[11]
Pfizer
North and 
South America, 
Europe, Asia
Pooled analyses 
from two non-
comparative 
Phase III trials[5]
and  RCT 
comparing IM and 
SC DMPA [9]
1 year, 2-3 years
Women, ages 18 to 49, 
with history of regular 
menstruation and 
desiring injectable 
contraception 
Excluded women with 
OC, implant or 
hormonal IUD use 
within previous 2 
months and DMPA-IM 
within 10 months of 
enrolment, known 
Healthy 
women
DMPA-SC 
and DMPA-
IM users
Median weight gain at 36 months (overall)
DMPA-SC:4.5 + 8.5 kg
DMPA-IM: 5.8 + 8.7 kg
No significant differences in median weight gain by 
BMI subgroups (< 25, >25 to < 30, >30 kg/m2) in any 
study. Data presented graphically in article.  
No consistent differences in the distribution of weight 
change across age groups (<25, >25 to 35, >35 years). 
Strengths
Multi-country design
Height and weight measured at baseline 
and weight measured every 3 months 
during follow-up
Weaknesses
No non-POC comparison group
II-2, 
fair
pregnancy or infertility 
or medical 
contraindications
Burke et al., 
2014 [21]
USAID
Senegal, 
Uganda
Prospective, open-
label 
observational 
study
July 2012-
November 2012
Women, ages 18 to 40, 
self-reported good 
health, continuous 
DMPA-IM users in last 
six months with most 
recent injection within 
15 weeks of enrolment
Healthy 
women
DMPA-SC 
and DMPA-
IM users
34 adverse events were recorded by 25 participants; 28 
in Uganda and 6 in Senegal 
Only 10 (9 in Uganda; 1 in Senegal) possibly or 
definitely related to DMPA-SC and mild to moderate 
severity: 
- 3 related to skin irritation
- 7 were known side effects of DMPA
All resolved without sequelae.
No pregnancies were reported. 
Strengths
Multi-country design
Weaknesses
No comparison group
III, 
fair
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Individual study: Each study was first given a rating based
on the study design (Table 1). Each study was also given a
rating of poor, fair, or good based on the criteria for grading
the internal validity of a study (Table 2). A good study meets
all criteria for that study design, a fair study does not meet all
criteria but is judged to have no fatal flaw, and a poor study
contains a fatal flaw. Also, the type of evidence was either
identified as being direct (the evidence was based on data
directly addressing the question) or indirect (the evidence
was extrapolated from other relevant data).References
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